Trial Profile
Effects of DPP-4 Inhibitor Therapy on Renal Sodium Handling and Renal Hemodynamics in Type 2 Diabetes Patients. The INDORSE Study: Inhibition of Dipeptidyl Peptidase IV: Outcomes on Renal Sodium Excretion
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms INDORSE
- 30 May 2017 New trial record
- 26 May 2017 Results published in the Diabetes Care
- 26 May 2017 Status changed from recruiting to completed, according to the results published in the Diabetes Care